FSSAI's Food Safety and Standards Regulations 2022 provide the relevant framework for nutraceutical manufacturing in India, including small batches. A 500-unit run does not remove the need for GMP records. GMP is a process framework, not a volume threshold. Smaller production may reduce record complexity, but it does not eliminate the records.
What GMP-aligned manufacturing means in practice
Good Manufacturing Practice sets controls for how a product is made, checked, and recorded. In India, nutraceutical production is governed primarily by FSSAI's Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations 2022, together with general food business operator licensing under the FSS Act.
In practice, GMP-aligned work requires written instructions for each manufacturing step, evidence that those instructions were followed, documented and assessed deviations, a traceable history for every batch, and finished-product testing before release.
At Leumas, calling our work GMP-aligned means these controls apply across batch sizes. A 500-unit pilot follows the same documented process as a 5,000-unit production run. The batch record is the production record itself, not merely a summary.
Documentation included for small batches
For a 500-unit capsule fill, the end-of-production package includes a Certificate of Analysis, batch record digest, ingredient traceability report, and deviation log. For a routine batch without out-of-specification events, the deviation log is typically blank.
The Certificate of Analysis records finished-product results, including identity of declared actives, microbial limits testing, total aerobic microbial count, total yeast and mould count, and absence of specified pathogens where required. Where applicable, it includes potency assay results for quantifiable vitamins and actives. Some formula categories also require heavy metals screening based on ingredient risk.
The batch record digest condenses the full production record. It lists raw-material lot numbers, in-process weight-check data, equipment identifiers, operator records, and the environmental condition log for the production area. A brand can provide it to a retailer or distributor as production documentation. It contains the details a buyer's technical team would typically request.
The ingredient traceability report links every ingredient lot used to its source CoA and incoming quality-check result. It records the chain of custody from supplier receipt through the finished batch.
How batch size changes GMP work in practice
The core documentation is largely unchanged. Differences appear in a small number of operational areas.
Sampling at small scale requires documented judgment. Pharmacopoeial guidance for microbial testing sets sample quantities with reference to batch size. For a 500-unit batch, fewer units may be tested in absolute terms, but the sampling basis must remain documented and defensible. We apply a risk-based approach: formulas containing botanical extracts from regions with documented contamination risk, or high-moisture-sensitive actives, receive more intensive testing than lower-risk vitamin blends.
Small batches hold a larger share of output as retain samples. Retaining 30 units from a 500-unit batch for stability and reference represents 6 percent of output. The same retain count in a 50,000-unit batch represents 0.06 percent. Stability and testing requirements, rather than batch size alone, set the absolute retain quantity.
Line clearance follows the same process at every batch size. The cleanroom is cleared, equipment surfaces are inspected and wiped per SOP, and the line clearance form is completed before the next batch begins. On a flexible line, products change more frequently than on a single-product dedicated line, so this control occurs more often and demands close attention.
Questions to ask a CDMO about GMP records
When assessing a nutraceutical contract manufacturer, ask for a sample CoA from a similar dosage form and a previous batch. Ask whether it maintains a deviation log and whether you will receive your batch's copy. For out-of-specification results, ask whether the process is batch rejection, investigation, and retesting, or simply shipment. Also ask about the retain-sample policy and holding period.
These questions separate a manufacturer with documented quality procedures from one that tests the finished batch without keeping the production records that support those results.
What GMP-aligned does not mean for export markets
The distinction matters: GMP-aligned production under FSSAI's nutraceutical regulations is a foundation, not automatic compliance with every export market. The US FDA's Current Good Manufacturing Practice rules for dietary supplements, 21 CFR Part 111, contain requirements that differ from India's FSSAI framework, including identity testing for every ingredient lot and defined batch production record retention. The EU food supplement framework also has national implementation variations across member states.
For a brand planning US or EU exports, our facility's documentation package is a credible starting point. Its sufficiency depends on the product category, the target country's regulatory treatment, and the import partner's compliance requirements. Brands should consult their own regulatory counsel before committing to an export production run.
Our GMP-aligned practices document the work performed and give brands flexibility in downstream use. Whether that documentation meets a particular market's requirements is for the brand's regulatory advisor to determine.